These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35185113)

  • 1. Comparison of the Lipidomic Signature of Fatty Liver in Children and Adults: A Cross-Sectional Study.
    Mann JP; Jenkins B; Furse S; Snowden SG; Alisi A; Draijer LG; Karnebeek K; Kelly DA; Koot BG; Mosca A; Salvestrini C; van Mourik I; Vreugdenhil A; Zilbauer M; Koulman A;
    J Pediatr Gastroenterol Nutr; 2022 Jun; 74(6):734-741. PubMed ID: 35185113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-alcoholic fatty liver disease is characterised by a reduced polyunsaturated fatty acid transport via free fatty acids and high-density lipoproteins (HDL).
    Mocciaro G; Allison M; Jenkins B; Azzu V; Huang-Doran I; Herrera-Marcos LV; Hall Z; Murgia A; Susan D; Frontini M; Vidal-Puig A; Koulman A; Griffin JL; Vacca M
    Mol Metab; 2023 Jul; 73():101728. PubMed ID: 37084865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
    Ooi GJ; Meikle PJ; Huynh K; Earnest A; Roberts SK; Kemp W; Parker BL; Brown W; Burton P; Watt MJ
    J Hepatol; 2021 Sep; 75(3):524-535. PubMed ID: 33887358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
    Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of chronic HBV infection on lipid metabolism in non-alcoholic fatty liver disease: A lipidomic analysis.
    Li H; Xu QY; Xie Y; Luo JJ; Cao HX; Pan Q
    Ann Hepatol; 2021; 24():100316. PubMed ID: 33515803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating lipidomic alterations in obese and non-obese subjects with non-alcoholic fatty liver disease.
    Jung Y; Lee MK; Puri P; Koo BK; Joo SK; Jang SY; Lee DH; Jung YJ; Kim BG; Lee KL; Park TS; Kang KT; Ryu DH; Kang SW; Kim D; Oh S; Kim W; Hwang GS
    Aliment Pharmacol Ther; 2020 Nov; 52(10):1603-1614. PubMed ID: 32892365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipidomic Analysis of the Protective Effects of Shenling Baizhu San on Non-Alcoholic Fatty Liver Disease in Rats.
    Deng Y; Pan M; Nie H; Zheng C; Tang K; Zhang Y; Yang Q
    Molecules; 2019 Oct; 24(21):. PubMed ID: 31683679
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Xu QY; Li H; Cao HX; Pan Q; Fan JG
    Biomed Res Int; 2020; 2020():8869674. PubMed ID: 33294458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic Lipidomics and Molecular Imaging in a Murine Non-Alcoholic Fatty Liver Disease Model: Insights into Molecular Mechanisms.
    Rodríguez-Calvo R; Samino S; Girona J; Martínez-Micaelo N; Ràfols P; García-Altares M; Guaita-Esteruelas S; Junza A; Heras M; Yanes O; Correig X; Masana L
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32899418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication.
    Israelsen M; Kim M; Suvitaival T; Madsen BS; Hansen CD; Torp N; Trost K; Thiele M; Hansen T; Legido-Quigley C; Krag A;
    JHEP Rep; 2021 Oct; 3(5):100325. PubMed ID: 34401690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-invasive assessment of hepatic lipid subspecies matched with non-alcoholic fatty liver disease phenotype.
    Erickson ML; Haus JM; Malin SK; Flask CA; McCullough AJ; Kirwan JP
    Nutr Metab Cardiovasc Dis; 2019 Nov; 29(11):1197-1204. PubMed ID: 31371265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum lipids are associated with nonalcoholic fatty liver disease: a pilot case-control study in Mexico.
    Flores YN; Amoon AT; Su B; Velazquez-Cruz R; Ramírez-Palacios P; Salmerón J; Rivera-Paredez B; Sinsheimer JS; Lusis AJ; Huertas-Vazquez A; Saab S; Glenn BA; May FP; Williams KJ; Bastani R; Bensinger SJ
    Lipids Health Dis; 2021 Oct; 20(1):136. PubMed ID: 34629052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease.
    Wasilewska N; Bobrus-Chociej A; Harasim-Symbor E; Tarasów E; Wojtkowska M; Chabowski A; Lebensztejn DM
    Lipids Health Dis; 2018 Sep; 17(1):216. PubMed ID: 30208901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between remnant lipoprotein cholesterol levels and non-alcoholic fatty liver disease in adolescents.
    Chin J; Mori TA; Adams LA; Beilin LJ; Huang RC; Olynyk JK; Ayonrinde OT
    JHEP Rep; 2020 Dec; 2(6):100150. PubMed ID: 32984791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A serum lipidomic study of patients with non-alcoholic fatty liver disease].
    Yang RX; Hu CX; Mi YQ; Sun WL; Chen GY; Pan Q; Shen F; Xu GW; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):122-127. PubMed ID: 28297799
    [No Abstract]   [Full Text] [Related]  

  • 17. Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology.
    Calvo N; Beltrán-Debón R; Rodríguez-Gallego E; Hernández-Aguilera A; Guirro M; Mariné-Casadó R; Millá L; Alegret JM; Sabench F; del Castillo D; Vinaixa M; Rodríguez MÀ; Correig X; García-Álvarez R; Menendez JA; Camps J; Joven J
    World J Gastroenterol; 2015 Jun; 21(24):7529-44. PubMed ID: 26140000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between plasminogen activator inhibitor-1 and severity of liver injury and cardiovascular risk in children with non-alcoholic fatty liver disease.
    Jin R; Krasinskas A; Le NA; Konomi JV; Holzberg J; Romero R; Vos MB
    Pediatr Obes; 2018 Jan; 13(1):23-29. PubMed ID: 27764892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipidomics in Nonalcoholic Fatty Liver Disease: Exploring Serum Lipids as Biomarkers for Pediatric Nonalcoholic Fatty Liver Disease.
    Draijer LG; Froon-Torenstra D; van Weeghel M; Vaz FM; Bohte AE; Holleboom AG; Benninga MA; Koot BGP
    J Pediatr Gastroenterol Nutr; 2020 Oct; 71(4):433-439. PubMed ID: 32947564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in paediatric nonalcoholic fatty liver disease: Role of lipidomics.
    Di Sessa A; Riccio S; Pirozzi E; Verde M; Passaro AP; Umano GR; Guarino S; Miraglia Del Giudice E; Marzuillo P
    World J Gastroenterol; 2021 Jul; 27(25):3815-3824. PubMed ID: 34321846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.